文献速递传染病防控与疫情报告

微小扇头蜱丝氨酸蛋白酶抑制剂17(RmS-17)中和表位的体外鉴定

In vitro identification of neutralizing epitopes of Rhipicephalus microplus serpin 17 (RmS-17).
PubMed 文献 · Vaccine · 2024-07-26

研究通过计算机表位预测与重叠肽ELISA筛选鉴定了微小扇头蜱丝氨酸蛋白酶抑制剂17(RmS-17)的B细胞表位,并用合成肽制备兔抗血清,发现针对p3RmS-17和p4RmS-17的抗体可部分中和RmS-17活性,支持基于表位的疫苗用于抗微小扇头蜱免疫的可能性。

要点

  • 计算机表位预测筛选出9个潜在B细胞表位区域,选定p1RmS-17和p2RmS-17用于实验。
  • 重叠肽ELISA鉴定出8个抗体结合区域,选定p3RmS-17和p4RmS-17。
  • 抗p3RmS-17和p4RmS-17抗体可部分中和RmS-17活性,提示表位疫苗可行性。

核心结论

  • 针对单一表位的抗体足以部分中和RmS-17活性。
  • 这些发现支持使用基于表位的疫苗进行抗微小扇头蜱免疫的可能性。

研究设计与样本

  • 采用计算机方法结合线性B细胞表位与抗原性预测器进行RmS-17表位定位。
  • 使用重叠肽进行ELISA筛选进行表位定位。
  • 基于预测合成肽并用于制备兔抗血清,纯化IgG评估抗体中和RmS-17的能力。

主要发现

  • 计算机定位筛选出9个潜在B细胞表位区域,基于抗原预测选定p1RmS-17和p2RmS-17用于实验。
  • 重叠肽ELISA筛选鉴定出8个抗体结合区域,选定p3RmS-17和p4RmS-17。
  • 针对p3RmS-17和p4RmS-17产生的抗体部分中和RmS-17活性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rhipicephalus microplus poses a significant problem for livestock worldwide and is primarily controlled with synthetic acaricides. The continuous use of acaricides results in the selection of resistance and causes environmental harm. Vaccination presents an alternative solution to this problem, although searching for the suitable antigen is still a work in progress. Salivary proteins hold promise for inclusion in vaccine formulation due to their roles in modulating host responses, assisting blood feeding and pathogen transmission. Serpins are a class of proteinase inhibitors and are among the molecules found in tick saliva that modulate host blood coagulation, inflammation, and adaptive immune responses. Previous studies have demonstrated the potential of R. microplus serpin 17 (RmS-17) to interfere with the host's defenses, and antibodies have been shown to neutralize its effects. This makes RmS-17 an putative target for vaccine development. METHODS: Epitope mapping of RmS-17 was achieved using in silico approach combining linear B-cell epitope and antigenicity predictor. In addition, epitope mapping using overlapping peptides in an ELISA screening was used. The serpin tridimensional structure and the epitopes spatial location within the molecule were determined. Peptides were synthetized based on the predictions and used for the production of rabbit anti-sera. Purified IgG's were used to assess the antibodies capacity to neutralize RmS-17. RESULTS: Through in silico mapping, nine potential B cell epitope regions were screened, with p1RmS-17 and p2RmS-17 selected for the experiment based on antigen prediction. In the ELISA screening using overlapping peptides, eight antibody-binding regions were identified, and p3RmS-17 and p4RmS-17 were chosen. Antibodies raised against p3RmS-17 and p4RmS-17 partially neutralized RmS-17 activity. CONCLUSION: It was found that antibodies against a single epitope are sufficient to partially neutralize RmS-17 activity. These findings support the possibility of using an epitope-based vaccine for immunization against R. microplus.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. de Albuquerque PMM, Kotál J, Juliano MA, et al. In vitro identification of neutralizing epitopes of Rhipicephalus microplus serpin 17 (RmS-17). Vaccine. 2024. PMID: 39060200. doi:10.1016/j.vaccine.2024.126161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。